Drugs affecting Cardiovascular system

salmanhabeebek 19,262 views 96 slides Mar 17, 2017
Slide 1
Slide 1 of 96
Slide 1
1
Slide 2
2
Slide 3
3
Slide 4
4
Slide 5
5
Slide 6
6
Slide 7
7
Slide 8
8
Slide 9
9
Slide 10
10
Slide 11
11
Slide 12
12
Slide 13
13
Slide 14
14
Slide 15
15
Slide 16
16
Slide 17
17
Slide 18
18
Slide 19
19
Slide 20
20
Slide 21
21
Slide 22
22
Slide 23
23
Slide 24
24
Slide 25
25
Slide 26
26
Slide 27
27
Slide 28
28
Slide 29
29
Slide 30
30
Slide 31
31
Slide 32
32
Slide 33
33
Slide 34
34
Slide 35
35
Slide 36
36
Slide 37
37
Slide 38
38
Slide 39
39
Slide 40
40
Slide 41
41
Slide 42
42
Slide 43
43
Slide 44
44
Slide 45
45
Slide 46
46
Slide 47
47
Slide 48
48
Slide 49
49
Slide 50
50
Slide 51
51
Slide 52
52
Slide 53
53
Slide 54
54
Slide 55
55
Slide 56
56
Slide 57
57
Slide 58
58
Slide 59
59
Slide 60
60
Slide 61
61
Slide 62
62
Slide 63
63
Slide 64
64
Slide 65
65
Slide 66
66
Slide 67
67
Slide 68
68
Slide 69
69
Slide 70
70
Slide 71
71
Slide 72
72
Slide 73
73
Slide 74
74
Slide 75
75
Slide 76
76
Slide 77
77
Slide 78
78
Slide 79
79
Slide 80
80
Slide 81
81
Slide 82
82
Slide 83
83
Slide 84
84
Slide 85
85
Slide 86
86
Slide 87
87
Slide 88
88
Slide 89
89
Slide 90
90
Slide 91
91
Slide 92
92
Slide 93
93
Slide 94
94
Slide 95
95
Slide 96
96

About This Presentation

Drugs affecting Cardiovascular system


Slide Content

DRUGS AFFECTING
CARDIOVASCULAR SYSTEM

CARDIOTONICS

?
•Cardiotonic agents are drugs used to
increase the contractility and output in a
hypodynamic heart without propotionate
increase in 02 consumption
•Commonly used in the treatment of heart
failure (HF)

•Cardiotonic (inotropic) drugs affect the
intracellular calcium levels in the heart
muscle, leading to increased contractility.
•This increase in contraction strength leads
to increased cardiac output, which causes
increased renal blood flow and increased
urine production

TYPES
1.Cardiac glycosides
2.Phosphodiesterase inhibitors

CARDIAC GLYCOSIDES
•Digoxin (Lanoxin) commonly used drug
•The cardiac glycosides were originally
derived from Digitalis purpurea (Common
Foxglove)

Foxglove plant
Digitalis lanata

Mechanism of action
•Digoxin increases intracellular calcium and
allows more calcium to enter myocardial
cells during depolarization. That results
1. Increased force of myocardial
contraction (a positive inotropic effect)
2. • Increased cardiac output and renal
perfusion

3. Slowed heart rate, owing to slowing of the
rate of cellular repolarization (a negative
chronotropic effect)
4.Decreased conduction velocity through the
atrioventricular(AV) node

INDICATIONS
•Heart failure (HF)
•Atrial flutter
•Atrial fibrillation
•Paroxysmal atrial tachycardia

Dosage
•Digoxin is available for oral and parenteral
administration.
•Oral- 0.75–1.25 mg PO
•IV-0.125–0.25 mg IV
• Onset of action - 30–120 minutes when
taken orally, 5–30 minutes when given
intravenously

Contraindications
•hypersensitivity to digitalis preparations
•ventricular tachycardia or fibrillation
•heart block or sick sinus syndrome
•idiopathic hypertrophic subaortic stenosis
(IHSS)
•acute MI
•Renal failure

Adverse Effects
•headache, weakness, drowsiness and
vision changes
•Digitalis toxicity ( serious side effect)

Digitalis toxicity
•A serious syndrome that can occur when
digoxin levels are too high
•Normal level- 0.5 -2.0 ng/ml
signs and symptoms – anorexia, nausea,
vomiting, malaise, depression, irregular
heart rhythms including heart block, atrial
arrhythmias, and ventricular tachycardia

•Antidote- Digoxin immune Fab (DigiFab)

Nurses responsibilities
•Assess for contraindications or cautions
•Perform a physical assessment
•Assess cardiac status closely, including
pulse and blood pressure
•Monitor apical pulse for 1 full minute
before administering the drug

•Hold the dose if the pulse is less than 60
beats/min in an adult or less than 90
beats/min in an infant; retake the pulse in
1 hour. If the pulse remains low, document
it, withhold the drug, and notify the
prescriber
•Monitor the pulse for any change in quality
or rhythm

•Administer intravenous doses very slowly
over at least 5 minutes to avoid cardiac
arrhythmias and adverse effects.
•Avoid administering the oral drug with food
or antacids to avoid delays in absorption
•Obtain digoxin level as ordered; monitor
the patient for therapeutic digoxin level
(0.5–2 ng/mL)

•Maintain emergency equipment on
standby if digoxin toxicity develops
•Provide thorough patient teaching,
including the name of the drug, dosage
prescribed, technique for monitoring pulse
and acceptable pulse parameters, dietary
measures if appropriate, measures to
avoid adverse effects, warning signs of
possible toxicity and need to notify health
care provider

PHOSPHODIESTERASE
INHIBITORS
•milrinone (Primacor)
•This drugs block the enzyme
phosphodiesterase.This blocking effect
leads to an increase in myocardial cell
cyclic adenosine monophosphate (cAMP),
which increases calcium levels in the cell

INDICATIONS
•short-term treatment of HF that has not
responded to digoxin or diuretics alone or
that has had a poor response to digoxin,
diuretics, and vasodilators

DOSAGE
•Intravenous
•(PRIMACOR IV 10Mg/ml inj)
dose- 50 microgram/kg iv bolus followed
by 0.4-1.0 microgram/kg/min infusion

Contraindications
•hypersensitivity to phosphodiesterase
inhibitors
•severe aortic or pulmonic valvular disease
•acute MI

Adverse Effects
•ventricular arrhythmias (which can
progress to fatal ventricular fibrillation),
hypotension, and chest pain
•GI effects include nausea, vomiting,
anorexia, and abdominal pain
•Thrombocytopenia occurs frequently with
milrinone

•Precipitates form when these drugs are
given in solution with furosemide

Nurses responsibilities
•Assess for contraindications or cautions:
any known allergies to these drugs or to
avoid hypersensitivity reactions;
•acute aortic or pulmonic valvular disease,
•acute myocardial infarction
•ventricular arrhythmias

•Pregnancy and lactation
•Assess cardiac status closely, including
pulse and blood pressure
•Protect the drug from light to prevent drug
degradation
•Monitor input and output and record daily
weight

•Monitor platelet counts before and
regularly during therapy to ensure that the
dose is appropriate, inspect the skin for
bruising or petechiae to detect early signs
of thrombocytopenia
•Provide life-support equipment on standby

•Provide thorough patient teaching,
including the name of the drug, dosage
prescribed, measures to avoid adverse
effects, warning signs of problems, and
the need for periodic monitoring and
evaluation

ANTIANGINALS

ANGINA
•It is a pain syndrome due to induction of
an adverse oxygen supply/demand
situation in a portion of myocardium

•Antianginal drugs are used to help restore
the appropriate supply-and-demand ratio
in oxygen delivery to the myocardium.

How they act
•These drugs can work to improve blood
delivery to the heart muscle
•(1) by dilating blood vessels
(i.e.,increasing the supply of oxygen)
(2) by decreasing the work of the heart
(i.e.decreasing the demand for oxygen).

Classification
•Nitrates
a. short acting nitrates
Eg: Glyceryl trinitrate (Nitroglycerine)
b.Long acting nitrates
Eg; Isosorbide dinitrate (sorbitrate)
•betA-BLOCKERS
Eg; Atenelol, Propanalol

•Calcium channel blockers
a. phenyl alkamine
Eg: verapamil
b. benzothiazepine
Eg: Diltiazem
c. Dihydropyridines
Eg: Nifidipine, Amlodipine

•Potassium channel openers
Eg: Nicorandil
•OTHers
Eg: Ivabradine

Nitrates
•Nitrates are drugs that act directly on
smooth muscle to cause relaxation and to
depress muscle tone
•isosorbide dinitrate (Isordil)
•isosorbide mononitrate
•nitroglycerin

Mechanism of action
•The nitrates relax and dilate veins,
arteries, and capillaries, allowing
increased blood fl ow through the vessels
and lowering systemic blood pressure
because of a drop in resistance.
•Nitrates decreases the preload and
afterload

INDICATIONS
•LONG ACTING NITRATES
Taken before chest pain begins in situations in
which exertion or stress can be anticipated for
prevention of angina in adults; taken daily for
management of chronic angina
SHORT ACTING NITRATES
•Treatment of acute angina attack; prevention of
anginal attacks

AVAILABLE FORMS
•Nitroglycerin is available as
•sublingual tablet,
•Translingual spray,
• Intravenous solution
•Transdermal patch,
•Topical ointmentor paste,
•Transmucosal agent

DOSAGE
•Isosorbide nitrate- 2.5–5 mg SL
5-mg chewable tablet;
5–20 mg PO;
•Nitroglycerin- 5 mcg/min via IV infusion

pump every 3–5 min;
•0.4-mg metered dose sublingual, up to
three doses in 15 min for acute attack

Contraindications
•Hypersensitivity
•Severe anemia
•Head trauma or cerebral hemorrhage
•pregnancy or lactation

Adverse effect
•Central nervous system (CNS)
headache, dizziness, and weakness
•Gastrointestinal (GI)
nausea, vomiting, and incontinence.
Cardiovascular
Hypotension
•Integumentary
flushing, pallor, increased perspiration.

Nurses responsibilities
•Assess for contraindications
•Assess cardiopulmonary status closely,
including pulse rate, blood pressure, heart
rate, and rhythm (30min)
•Always check the expiration date on the
bottle and protect the medication from
heat and light
•Instruct the patient that a sublingual dose
may be repeated in 5 minutes if relief is

is not felt, for a total of three doses; if pain
persists, the patient should go to an
emergency room
•Rotate the sites of topical form
•Taper the dose gradually (over 4 to 6
weeks) after long-term therapy

BETA BLOCKERS
•Beta-adrenergic blockers are used to
block the stimulatory effects of the
sympathetic nervous system.
•Eg- Atenelol
Propanalol
Metoprolol

Mechanism of action
•The beta-blockers competitively block
beta-adrenergic receptors in the heart and
decreasing the influence of the SNS on
these tissues. The result is a decrease in
the excitability of the heart, a decrease in
cardiac output, a decrease in cardiac
oxygen consumption, and a lowering
of blood pressure.

INDICATIONS
•Long-term management of angina
pectoris.
•To prevent reinfarction in stable patients 1
to 4 weeks after an MI

CONTRAINDICATIONS
•Bradycardia, heart block, and cardiogenic
shock
•Pregnancy and lactation
•Cautious administration to Asthma,
chronic obstructive pulmonary disease, or
thyrotoxicosis

DOASGE
•ORAL- 50-100 mg
•INTRAVENOUS - 5mg -15mg

NURSES RESPONSIBILITY
•Assess for contraindications or cautions
•Do not stop these drugs abruptly after
chronic therapy, but taper gradually over 2
weeks
•Monitor blood pressure, pulse, rhythm,
and cardiac output regularly
•Continuously monitor any patient receiving
an intravenous form of these drugs

CALCIUM CHANNEL BLOCKERS
•amlodipine (Norvasc),
•diltiazem (Cardizem)
•nicardipine (Cardene)
•nifedipine
•verapamil (Calan, Isoptin).

MECHANISM OF ACTION
•Calcium channel blockers inhibit the
movement of calcium ions across the
membranes of myocardial and arterial
muscle cells, altering the action potential
and blocking muscle cell contraction.
•This will results loss of smooth muscle
tone, vasodilation, and decreased
peripheral resistance occur

•Decreases the preload and afterload
which results in decreases cardiac
workload and oxygen consumption.

INDICATIONS
Treatment of
•Prinzmetal angina
•Chronic angina
•Effort associated angina
•Hypertension.
•Verapamil is also used to treat cardiac
tachyarrhythmias because it slows
conduction more than the other calcium
channel blockers do

Contraindications
•Hypersensitivity
•Pregnancy and lactation
Caution should be used with
•heart block or sick sinus syndrome
•Renal or hepatic dysfunction
•Heart Failure ,

Adverse Effects
•CNS -dizziness, light-headedness,
headache, and fatigue.
•GI- nausea and hepatic injury related to
direct toxic effects on hepatic cells.
Cardiovascular -hypotension, bradycardia,
peripheral edema, and heart block.
•Skin- flushing and rash

NURSES RESPONSIBILITIES
•Assess for contraindications
•Inspect skin for color and integrity
•Monitor blood pressure very carefully
•Provide thorough patient teaching

Potassium channel openers
•Potassium channel openers activates the
ATP sensitive potassium channels thereby
hyperpolarising the vascular smooth
muscles.
•This results in reduction in vascular tone
•That will lead to a decrease in preload and
afterload
•EG- Nicorandil

Dosage
•Oral- 5-20mg

INDICATIONS
•Prevention and long term treatment of
chronic stable angina pectoris
•Reduction in the risk of acute coronary
syndromes in patients with chronic stable
angina

contraindications
•Hypersensitivity
•Cardiogenic shock
•hypotension

Side effects
•Flushing
•Palpitation
•Weakness
•Headache
•Dizziness
•vomiting

Nurses responsibility
•Assess the hypersensitivity and
contraindications
•Regular monitoring of vital signs
•Health education
• asses the oral cavity for oral ulcers

OTHERS- IVABRADINE
•Ivabradine is a newer type of drug
•Mechnism of action- it acts by reducing
the heart rate by specific inhibition of the
funny
channel (cyclic nucleotide-gated)
•It specifically inhibits the cardiac
pacemaker and therby reducing heart
rate

indications
•Chronic stable angina patients with normal
sinus rhythm
•Chronic heart failure

Dosage
•Oral- 2.5-5mg

Contraindications
•Resting heart rate less than 70
•Cardiogenic shock
•Acute M I
•Sick sinus syndrome
•Severe hepatic injury
•Pregnency and lactation

Side effects
•Blurred vision
•Bradycardia
•Syncope
•Headache
•Constipation
•Muscle cramps

Nurses responsibility
•Check for hypersensitivity and
contraindications
•Assess the pulse rate and blood pressure
•Check the liver function test regularly
•Check for visual disturbances
•Health education

ANTIHYPERTENSIV
ES

?
HYPERTENSION

•REGULATORS OF BLOOD
PRESSURE ?

•Antihypertensives are the drugs that used
to treat hypertension

CLASSIFICATIONS
•DIURETICS
LOOP DIURETICS
Eg- furosemide
THIAZIDE DIURETICS
Eg- Hydrochlorothiazide
POTASSIUM SPARING DIURETICS
Eg- Spirinolactone

ADRENERGIC inhibitors
•CENTRALLY ACTING α- ADRENERGIC
ANTAGONISTS
Eg- Clonidine
•PERIPHERALLY ACTING α- ADRENERGIC
ANTAGONISTS
Eg- Reserpine
• α- ADRENERGIC BLOCKERS
Eg-Prazocin

•β- ADRENERGIC BLOCKERS
Eg- Atenelol
•Calcium Channel Blockers
Eg- Amlodipine
Nifidipine

ANGIOTENSIN INHIBITORS
•ANGIOTENSIN-CONVERTING
ENZYME (ACE) INHIBITORS
Eg- Captopril, Enalapril
•Angiotensin II–Receptor
Blockers
Eg- Losartan
Telmisartan
•Vasodilators
Eg- Nitroglycerin

•DIRECT VASODILATORS
Eg- Nitroglycerin
Sodium nitroprusside

DIURETICS
Drugs that increase the production of urine

LOOP DIURETICS
They inhibit the sodium and chloride
reabsorption in the thick segment of the
ascending limb of the loop of Henle as well
as in the proximal convoluted tubule and the
distal diluting site
Eg- furosemide( Lasix)

Dosage
•40 mg PO t.i.d

Thiazide diuretics
Inhibit sodium and chloride reabsorption
in the distal convoluted tubule
•These drugs are the first-line drugs used to
manage essential hypertension when drug
therapy is needed

•Eg- Hydrochlorothiazide
•Dosage- 25–100 mg/d

Potassium Sparing Diuretics
•The potassium-sparing diuretics are not
as powerful as the loop diuretics, but they
retain potassium instead of wasting it
•Eg- spironolactone (Aldactone)
amiloride (Midamor)

Mechanism of action
•Spironolactone acts as an aldosterone
antagonist, blocking the actions of
aldosterone in the distal tubule.
•It decreases the elimination of potassium

Dosage
•50–100 mg/d PO

CONTRAINDICATIONS
•Hypersensitivity
•Fluid and electrolyte imbalances
•Severe renal failure
cautious administration with
Systemic lupus erythematous( SLE)
Gout
Pregnancy and lactation

SIDE EFFECTS
•Common side effects
GI upset
fluid and electrolyte imbalances
hypotension
electrolyte disturbances

•Side effects ( thiazide and loop diuretics)
1.hypokalemia
weakness, muscle cramps, and
arrhythmia
2. hypercalcemia
3. decreased excretion of uric acid

•Side effects ( potassium sparing diuretics)
1. Hyperkalemia
lethargy, confusion, ataxia, muscle

cramps, and cardiac arrhythmias.